Product Description
Sevoflurane is a halogenated inhalational anesthetic that is FDA approved for the induction and maintenance of general anesthesia in adults and pediatric patients for inpatient and outpatient surgery. Sevoflurane is a volatile anesthetic that provides hypnosis, amnesia, analgesia, akinesia, and autonomic blockade during surgical and procedural interventions. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK534781/)
Mechanisms of Action: GABA Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AZIENDA OSPEDALIERAN GERARDO DI MONZA
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Italy, Spain, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Acute Respiratory Distress Syndrome|Anesthesia Related
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TREX | P3 |
Active, not recruiting |
Anesthesia Related |
2026-03-01 |
|
| IPA Study | P3 |
Active, not recruiting |
Acute Respiratory Distress Syndrome |
2024-11-02 |
|
| 2022-003737-19 | P2 |
Active, not recruiting |
Unknown |
2023-12-13 |